Background: A Department of Health prostate awareness initiative, piloted in Coventry in 2006, promoted reporting of symptoms of benign prostatic hyperplasia, prostatitis and prostate cancer to GPs without causing sudden increases in workload. Qualitative evaluation showed a wide distribution of materials.
Objectives: Evaluation of effects of the pilot on rates of GP urological consultations, prescriptions and prostate-specific antigen (PSA) requests in general practice in Coventry and three control areas.
Methods: Data on GP consultations provided by the General Practice Research Database for three to five practices per area covered the periods 1 October 2005 to 31 March 2006 and 1 October 2006 to 31 March 2007. Pathology laboratory data on PSA requests covered 18 months from 1 December 2005 in consenting practices: 44/55 (80%) in Coventry and 102/159 (64%) in control areas. The rates of GP consultations for urological symptoms and of prescriptions issued for urological conditions per 100 person-years in men with no prior diagnosis of benign or malignant prostate disease and rates of PSA tests per 100 men were analysed.
Results: There was no significant change in consultation rates for urological symptoms over time in Coventry. The rate of prescriptions and of PSA testing increased in Coventry before the pilot began (P < 0.001) but there was no sudden increase after the pilot launch with similar trends in the control areas.
Conclusions: There was no increase in GP workload following the start of the pilot. Routine data can be used in evaluation but should be linked to surveys of awareness, health-seeking behaviour and delivery of campaign materials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/fampra/cmp081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network.
BioDrugs
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Background: Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burden. Biologic therapies targeting the interleukin (IL)-23/IL-17 axis have been widely used for PsO, but their comparative effectiveness in preventing PsA remains unclear.
Objective: The study objective was to compare the occurrence of developing incidental PsA among PsO patients treated with interleukin-23 inhibitors (IL23is) or interleukin-17 inhibitors (IL17is).
Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England.
Pharmacoecon Open
January 2025
Optimax Access Ltd, Kenneth Dibben House, Enterprise Rd, Chilworth, Southampton University Science Park, Southampton, UK.
Background: Patients with a left ventricular ejection fraction ≤ 35% are at increased risk of sudden cardiac death (SCD) within the first months after a myocardial infarction (MI). The wearable cardioverter defibrillator (WCD) is an established, safe and effective solution which can protect patients from SCD during the first months after an MI, when the risk of SCD is at its peak. This study aimed to evaluate the cost-effectiveness of WCD combined with guideline-directed medical therapy (GDMT) compared to GDMT alone, after MI in the English National Health Service (NHS).
View Article and Find Full Text PDFBackground: The Prostatype score (P-score) is a prognostic biomarker that integrates a three-gene (IGFBP3, F3, and VGLL3) signature derived from prostate biopsy samples, with key clinical parameters, including prostate-specific antigen (PSA) levels, Gleason grade, and tumor stage at diagnosis. The test has demonstrated superior predictive accuracy for prostate cancer outcomes compared with traditional risk categorization systems such as D'Amico. Notably, it reclassifies a higher proportion of patients into the low-risk category, making them eligible for active surveillance.
View Article and Find Full Text PDFIncrease in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study.
Rheumatol Int
January 2025
Department of Rheumatology, AIIMS, New Delhi, India.
Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities.
Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association.
PSA testing in primary care: is it time to change our practice?
BMC Prim Care
December 2024
Department of Urology, Erasmus Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Background: Historical prostate-specific antigen (PSA)-based screening studies reduced prostate cancer-related deaths but also led to overdiagnosis/overtreatment. Since then, opportunistic PSA testing has increased, and late-stage diagnoses and prostate-cancer related deaths are rising.
Objectives: To review current trends regarding PSA testing in primary care and propose a collaborative approach to improve early prostate cancer detection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!